USA ISM Non-Manufacturing PMI for Jun 55.300M vs 54.300 Est; Prior 55.900
USA ISM Non-Manufacturing PMI for Jun 55.300 million vs 54.300 consensus estimate. The prior reading was 55.900.
REV Group’s ENC Delivers Fleet Of E-Z Rider II Buses To San Francisco Municipal Transportation Agency
https://revgroup.com/enc-delivers-fleet-of-e-z-rider-ii-hybrid-electric-buses-to-san-francisco-municipal-transportation-agency/
USA S&P Global Composite PMI for Jun 52.300 vs 51.200 Est; Prior 51.200
USA S&P Global Composite PMI for Jun 52.300 vs 51.200 consensus estimate. The prior reading was 51.200.
Qualigen Therapeutics Announces Partnership With Hande Sciences To Scale-Up Manufacturing To Support IND-Enabling Studies For QN-302
Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing
Piper Sandler To Acquire DBO Partners; Terms Not Disclosed
Acquisition adds significant scale to Piper Sandler technology investment banking and positions team for future growth
Piper Sandler Companies (NYSE:PIPR), a leading investment bank, announced today that it has
Eos Energy Enterprises, Inc. Announces Two New Orders With Bridgelink Commodities And A Northeast Solar Developer; Says Backlog Now Over $460M
Eos Energy Enterprises, Inc. (NASDAQ:EOSE) ("Eos"), a leading provider of safe, scalable, efficient, and sustainable zinc-based energy storage systems, today announced the signing of two significant
Sheba Medical Center and Enlivex Announce Dosing Of The First Patient In Phase I/II Trial Evaluating Allocetra Combined With Chemotherapy In Patients With Peritoneal Metastases Arising From Solid Cancers
First clinical trial of Allocetra™ in patients with cancer builds upon promising preclinical studies demonstrating its broadly applicable immunotherapeutic effects in solid tumor models
Sheba Medical Center was
SciSparc Board Of Directors Authorizes Co. To Take Actions To Implement Buyback Program Of Up To $1M
SciSparc Ltd. (NASDAQ:SPRC) (the "Company" or "SciSparc"), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system,
Caladrius Biosciences And Cend Therapeutics Highlights Publication Of Pancreatic Cancer Trial Data In The Lancet Gastroenterology And Hepatology
Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies designed to treat or reverse disease, and Cend